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Abstract
Escape mutant (EM) virus that evades CD8+ T cell recognition is frequently observed following infection with HIV-1 or SIV.
This EM virus is often less replicatively ‘‘fit’’ compared to wild-type (WT) virus, as demonstrated by reversion to WT upon
transmission of HIV to a naı ¨ve host and the association of EM virus with lower viral load in vivo in HIV-1 infection. The rate
and timing of reversion is, however, highly variable. We quantified reversion to WT of a series of SIV and SHIV viruses
containing minor amounts of WT virus in pigtail macaques using a sensitive PCR assay. Infection with mixes of EM and WT
virus containing $10% WT virus results in immediate and rapid outgrowth of WT virus at SIV Gag CD8 T cell epitopes within
7 days of infection of pigtail macaques with SHIV or SIV. In contrast, infection with biologically passaged SHIVmn229 viruses
with much smaller proportions of WT sequence, or a molecular clone of pure EM SIVmac239, demonstrated a delayed or slow
pattern of reversion. WT virus was not detectable until $8 days after inoculation and took $8 weeks to become the
dominant quasispecies. A delayed pattern of reversion was associated with significantly lower viral loads. The diversity of
the infecting inoculum determines the timing of reversion to WT virus, which in turn predicts the outcome of infection. The
delay in reversion of fitness-reducing CD8 T cell escape mutations in some scenarios suggests opportunities to reduce the
pathogenicity of HIV during very early infection.
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Introduction
The high mutation rate of HIV coupled with the strong immune
selection pressure exerted by CD8+ T lymphocytes leads to the
frequent selection of ‘escape mutant’ (EM) virus that contains
mutations within CD8+ T cell epitopes that abrogates their
recognition and killing by T cells. Although these mutations confer
an advantage on EM virus, they also incur a ‘fitness cost’, as EM
virus often has lower replicative capacity than the original wild-
type (WT) virus, particularly when mutations occur in conserved
regions such as Gag [1,2]. This reduced replicative capacity of EM
virus leads to reversion from EM to WT virus in HIV-infected
humans and SIV-infected macaques following transmission to
naı ¨ve hosts that lack the appropriate MHC alleles to recognise the
epitope concerned [3–6]. There is strong evidence from a recent
study of over 100 human HIV-1 transmissions that lack of
reversion at multiple key Gag CD8 T cell epitopes is associated
with lower viral loads [7]. Thus, the fitness costs of escape
mutations contribute to partial viral control even when the epitope
is not recognised [8].
The rate of reversion from EM to WT in vivo is however highly
variable. Factors that impact the rate of immune escape and
reversion include the particular CD8 T cell epitope, target cell
availability, prior vaccination, the presence of compensatory
mutations, the MHC of the donor and recipient, and timing of
appearance of the mutation [7,9–13]. Both escape and reversion
have been observed to occur extremely rapidly in experimental
infection of macaques, but generally much more slowly in natural
HIV-1 infection. It has been suggested that the slow dynamics of
escape and reversion in HIV-1 implies lower immune pressure and
lower fitness costs of escape in HIV-1 [14]. However, this analysis
ignores potential differences in the size and diversity of the initial
inoculum in natural HIV and experimental SIV infection. Earlier
studies of HIV-1 infection in humans strongly suggested many, but
not all, transmission events are initiated with single virus
quasispecies [15–24]. Recent data using single genome amplifica-
tion strategies of over 100 subjects with acute HIV-1 infection
suggests that most (76%) subjects with HIV-1 infection acquire just
a single viral strain, while the rest (24%), acquire 2 or more
variants [25]. The ability of minor WT variants to outgrow a
dominant EM variant is difficult to evaluate in humans where the
infecting HIV-1 isolate(s) and timing of infection are not precisely
known and availability of samples prior to the peak of acute
infection is limited. Macaques can be infected with known
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study in vivo competition between EM and WT variants under
different conditions.
A considerable technical hurdle in evaluating the evolution of
immune escape variants is sensitively and specifically quantifying
minor variants. Cloning and sequencing is poorly quantitative for
variants of ,10% of the total unless prohibitively large numbers of
clones are analyzed. We recently developed quantitative real-time
PCRassays (qRT-PCRs) to studyescape mutations that emergeat 2
different SIV Gag CD8 T cell epitopes (KP9 and AF9) in pigtail
macaques [10,12]. These assays are sensitive to variants comprising
#0.01% of total virus, levels that would be almost impossible to
quantify with standard cloning and sequencing techniques. This
advancenowallowsustoquantifytheevolutionofboththeWTand
EM variants following inoculation with different mixes of WT and
EM virus. Specifically, we examined how the ratio of EM:WT virus
in the infecting inoculum affected the dynamics of reversion in vivo
and the impact of this on viral load in acute and chronic infection.
Methods
Animals
Experiments on outbred pigtail macaques (Macaca nemestrina)
were approved by the University of Melbourne and CSIRO
livestock industries Animal Ethics Committees. Pigtail macaques
were typed by reference strand-mediated conformational analysis
for the MHC-I alleles Mane-A*10 and Mane-A*17 allele which
present SIV Gag164–172 KP9 epitope and SIV Gag371–379 AF9
epitope respectively [26,27].
SHIVmn229 infection
Reversion of KP9 EM SHIVmn229 viruses (K165R) from 3
different viral inocula derived from pigtail macaques expressing
the restricting Mane-A*10 allele were assessed following passage of
each virus to 2–4 naı ¨ve Mane-A*10 negative pigtail macaques. We
studied reversion of the original SHIVmn229 stock in 4 animals as
previously described [10]. This original X4-tropic SHIVmn229
stock was derived following passage of SHIVHXB2 in Mane-A*10
positive pigtail macaques and is 89% EM and 11% WT at the
K165 position within the Gag KP9 epitope [5,10]. The typical
escape mutation at the KP9 epitope is a lysine to arginine change
at amino acid 165 of Gag (K165R).
Reversion of the K165R mutation back to WT was also studied
by transmission of further passages of the SHIVmn229, directly
from the serum / cells of two infected animals that showed escape
at the KP9 epitope. This passaged virus contained a much lower
level of WT virus than the original SHIVmn229 stock, and was
inoculated into 4 additional Mane-A*10 negative macaques. Two
macaques (6274 and 6366) received 1 ml of plasma and 3610
6
peripheral blood mononuclear cells (PBMC) from the donor Mane-
A*10+ animal 4296 8 weeks after SHIVmn229 infection. Two
additional macaques received plasma and serum samples from
Mane-A*10 positive animal 6279 11 weeks after SHIVmn229
infection. Animals 4296 and 6279 were previously described as
part of a DNA and Fowlpoxvirus vaccine studies in macaques
[28,29]. The DNA and Fowlpoxvirus vaccines expressed WT SIV
Gag, inducing KP9 specific CD8 T cells which force further
escape at KP9 following SHIVmn229 challenge [9]. Plasma samples
transferred at these time points contained 4.0% and 0.34% WT
virus respectively by qRT-PCR as described below.
To assess the pathogenicity of the EM viruses, we compared
viral loads of the passaged low WT SHIVmn229 with 21
unvaccinated control pigtail macaques previously infected with
the original SHIVmn229 stock (89:11 EM:WT) previously used
across several vaccine studies [28–30].
SHIVSF162P3 AF9 mutant virus
Reversion of AF9 was studied as previously described [31] in
two naive Mane-A*17 negative macaques infected with
SHIVSF162P3 passaged in vivo in a Mane-A*17+ pigtail macaque.
This passaged SHIV acquired a 6-nucleotide deletion within the
AF9 epitope [31]. The transmitted plasma contained approxi-
mately 50% WT virus and 50% EM virus at AF9 when measured
by qRT-PCR as described below [12].
K165R SIVmac239 molecular clone
To examine the effect of infection with pure pathogenic R5-
tropic KP9 EM virus, we used PCR mutagenesis techniques to
mutate the translated amino acid from lysine to arginine at Gag
position 165 within our previously described SIVmac239 proviral
plasmid [32]. Briefly, a specific mutation was introduced into the
9.9 kb 59 plasmid [32,33] using the QuikChange
TM II site-directed
mutagenesis kit according to the manufacturer’s protocol (Strata-
gene, La Jolla, CA). using the primers 59 -GGTAAAATTGATA-
GAGGAAAAGAGATTTGGAGCAGAAGTAGTGCC-39 and
59- GGCACTACTTCTGCTCCAAATCTCTTTTCCTCTAT-
CAATTTTACC-39. The mutated 59 vector and 39 vector of
SIVmac239 [32] were joined together by digesting with Sph I,
followed by ligation and transformation using TOP10 cells. The
authenticity of the resulting constructs were confirmed by double-
stranded DNA sequencing. We confirmed the K165R EM
SIVmac239 DNA was infectious in vitro by transfecting plasmids into
HeLa cells and testing the supernatants for their ability to infect
CEMX174 in vitro (not shown).
To initiate infections in vivo, we injected animals with 150 mgo f
the K165R SIVmac239 proviral DNA intramuscularly, a technique
we previously used to initiate infections with both WT and nef/
LTR-deleted SIVmac239 strains [32]. To model the effect of dual
WT and EM infection (similar to the biological SHIVmn229 stock
containing 11% WT virus at KP9), we also inoculated 2 animals
IM with 150 ug of a 90:10 mix of K165R EM and WT SIVmac239
proviral plasmids.
Quantitative real-time PCR
To quantify virus levels of WT or EM quasispecies at the KP9
and AF9 epitopes we employed recently published novel real-time
PCR assays [10,12]. The assays use a forward primer specific for
either wild-type sequence or specific for the nucleotide mutation
Author Summary
Understanding how to contain HIV replication by the
immune system is a key goal of vaccine strategies. HIV
frequently mutates to avoid immune recognition, but this
may come at a ‘‘fitness cost’’, weakening the virus. When
HIV is transmitted to a new host, the mutations often
revert back to wild-type, allowing the virus to regain a
fitter state. We found that when multiple HIV-like viruses
are transmitted to monkeys, containing both mutant and
wild-type, reversion to wild-type is very rapid and the fitter
virus results in higher viral levels. In contrast, when only
escape mutant virus initiates the infection, reversion to
wild-type is delayed to later during early infection, and
lower levels of virus result. Our results suggest that the
composition of the infecting virus plays a role in
determining the outcome of HIV infections. Strategies to
maintain weakened virus strains during the early HIV
infection may help the host control virus replication.
Reversion to Wild Type Correlates with Viral Load
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nucleotide deletion AF9 escape mutant. In short, for each time-
point after infection 10 ml of RNA extracted from EDTA-
anticoagulated plasma was subjected to reverse-transcription to
create cDNA that was then amplified by qRT-PCR using either
WT or EM primers specific for the appropriate SIV Gag epitope.
A reverse primer and 59 6FAM labelled Minor Groove Binding
(MGB)-DNA probe were also added for quantification against the
appropriate SIV Gag epitope RNA standards using the ABI Prism
7700 sequence detection system PCR thermal cycler or an
Eppendorf Realplex
4 cycler. Analysis was performed using SDS
applications version 1.9 (ABI) or Eppendorf Realplex
4 software.
Baselines were set 2 cycles earlier than real reported fluorescence
and threshold value was determined by setting threshold bar
within the linear data phase. Samples amplifying after 40 cycles
were regarded as negative, and corresponds to ,1.5-Log10 SHIV/
SIV RNA copies/ml of plasma (threshold value of quantification).
Rates of reversion
In order to compare the dynamics of reversion in different
animals we analysed reversion rates as previously described [5].
We defined reversion rate as the absolute difference in growth
rates between the wild type (W) and mutant (M) in a given time
interval. Briefly, if fW(t) is the fraction of wild type and fM(t) is the
fraction of escape mutant clones at time t, we calculate the time-
dependent reversion rate R from the proportions of clones of each
type at the end points ts and te of the time interval (ts, te),
Rt s, te ðÞ ~
ln fW te ðÞ =fM te ðÞ ½  {ln fW ts ðÞ =fM ts ðÞ ½ 
te{ts
: ð1Þ
The model of reversion
In order to explain the experimental results, we used a standard
model of viral dynamics applied to reversion [11]. In this model,
wild type (W) and escape mutant (M) virus with different, but
constant in time, replicative capacities, infect the same pool of
target cells T (in the case of SHIVmn229 these are all CD4+ T cells),
generating infected cells IW and IM respectively. This model is
described by the set of equations:
dT
dt
~l{dTT{bWWT{bMMT
dIW
dt
~bWWT{dIW
dIM
dt
~bMWT{dIM
dW
dt
~pIW{cW
dM
dt
~pIM{cM:
ð2Þ
In the system of Equation 2, target cells T are replaced from an
external source at the rate l and in the absence of infection are lost
at the rate dT. The difference in replicative capacities of WT and
EM is the result of different rates of infection of target cells (bW
and bM respectively, where bW.bM). Cells infected by both strains
die at the same rate d (since there is no immune response specific
to one strain). Both strains are produced from infected cells at the
same rate p and are cleared at the same rate c.
This model predicts the reversion rate in the time interval
between ts and te,
Rt s, te ðÞ ~ rW{rM ðÞ Tt s, te ðÞ ð 3Þ
where rW=bWp/c and rM=bMp/c are the replicative capacities of
WT and EM respectively, and Tt s, te ðÞ is the average number of
target cells in the interval (ts, te). The model gives the reversion rate
directly proportional to target cell number.
Results
A fitness cost is usually incurred by CD8 T cell escape mutations;
this is most clearly demonstrated when EM virus reverts to the fitter
WT upon transmission to MHC mismatched hosts [3–5,34]. Rapid
reversion of EM KP9 virus occurred in Mane-A*10 negative
macaques infected with our SHIVmn229 viral stock (Figure 1A). This
biological isolate is 11.2% WT by qRT-PCR (9.1% by cloning and
sequencing 44 clones) since it was derived from an infectious
SHIVHXB2 clone originally passaged in Mane-A*10+ pigtail
macaques [5]. In our first analysis, we compared reversion to WT
of our stock virus to that seen with two different passaged virus
innocula. In each case, naı ¨ve Mane-A*10 negative pigtail macaques
were infected with plasma and PBMC derived from further in vivo
passages of SHIVmn229 containing 3–30 fold lower proportions of
WT KP9 virus [5]. We also compared the rates of reversion at
another Gag epitope, AF9, for which we have also developed a
sensitive qRT-PCR for [31].
Outgrowth of WT virus following inoculation with the EM
SHIVmn229 stock (containing 89% EM virus and 11% WT virus) is
almost identical and very rapid in all Mane-A*10 negative animals
studied (Figure 1A, Table 1). WT virus grows most rapidly in the
early days of infection while the target cells are not yet depleted, to
dominate the viral population by the second week of infection.
The K165R EM virus decays to very minor or undetectable level
by day 56 of infection in all animals.
To investigate whether the rapid outgrowth of WT virus in the
setting of substantial levels of WT virus in the inoculum could be
generalized to other Gag epitopes, we studied rates of reversion at
the AF9 epitope. We inoculated 2 naı ¨ve Mane-A*17 negative
pigtail macaques with a passaged virus containing ,50% WT and
50% EM virus at AF9 [31]. Very similar rapid outgrowth of WT
virus was observed using separate specific qRT-PCRs for WT
virus or the 6-bp deletion AF9 mutation (Figure 1B). Again, WT
virus grows at a rapid rate over the first week and is the dominant
species over EM virus within 2 weeks of inoculation. Thus, where
both WT and EM viruses are present in substantial quantities in
the virus inoculum, the WT virus very rapidly outgrows the EM
virus upon transfer to MHC-mismatched hosts.
Outgrowth of WT virus delayed and slowed with lower
levels of WT in inoculum
The rapid outgrowth of WT virus in the previous experiments
suggested sufficient quantities of WT virus were present in the
inoculum to co-infect the host and then rapidly out-compete the
EM virus. We therefore sought to elucidate the impact of much
smaller amounts of WT KP9 on reversion at KP9. We first chose
to transfer plasma and cells from Mane-A*10+ animals infected for
lengthy periods of time with SHIVmn229 (essentially further in vivo
passages of the original SHIVHXB2 stock). For these virus transfer
experiments, we selected donor Mane-A*10+ animals that were
previously vaccinated with SIV Gag-expressing DNA and
recombinant Fowlpoxvirus vaccines [9,28,29]. The donor animals
Reversion to Wild Type Correlates with Viral Load
PLoS Pathogens | www.plospathogens.org 3 April 2009 | Volume 5 | Issue 4 | e1000378Figure 1. Reversion to WT for different viruses and percentages of WT in the inocula. (A–F) Shows WT (squares) and EM (triangles) plasma
viral loads over time by qRT-PCR from individual pigtail macaques inoculated with different viruses over 11 weeks. (A) SHIVmn229 stock with 11.2% WT
virus at KP9 CD8 T cell epitope (four animals) (B) In vivo passage of SHIVSF162P3 with 50% WT virus at AF9 CD8 T cell epitope (2 animals). (C) In vivo
passage of SHIVmn229 with 4.0% WT virus at KP9 (2 animals). (D) In vivo passage of SHIVmn229 with 0.34% WT virus at KP9 (two animals). (E) Mix of
SIVmac239 molecular clones containing 10% WT virus and 90% K165R EM virus. (F) Pure SIVmac239 molecular clone of 100% K165R EM virus (0% WT, 3
animals). (G) Mean (6SEM) of WT (upper panels) or EM (lower panels) viral loads of groups of animals given the same virus. Animals administered
mixes of EM and WT virus with $10% WT have similar WT and EM viral loads and are grouped together (left panels) in comparison to animals
administered viruses with ,10% WT content (right panels). The first 10 days are shaded to indicate the differences in WT virus expansion between
the two types of viruses.
doi:10.1371/journal.ppat.1000378.g001
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which are further boosted after virus challenge. The KP9-specific
responses in the donor animals select the EM virus and further
reduce levels of WT virus. By qRT-PCR, the passaged viruses
chosen had either only 4% WT virus or 0.34% WT virus at KP9
using our qRT-PCR (Figure 1C and 1D, and Table 1).
The viral transfer was successful, resulting in an infection of all
animals studied. The appearance of WT virus was delayed in
recipients of both in vivo passaged SHIVmn229, which contained
lower levels of WT virus (Figure 1C and 1D). Although high levels
of EM virus were detected within 6 days of transfer with the KP9
qRT-PCR, very low levels of WT virus were detected only by day
8–11 after transfer. Further, even after the detection of WT virus,
this variant did not expand dramatically to high levels as seen with
the original SHIVmn229 stock or the passaged AF9 mutant virus.
The WT virus took 63–75 days to exceed EM virus in the case of
the 4% WT stock, and WT virus levels never exceeded EM virus
levels to 75 days of follow up in the case of the 0.34% WT stock.
The kinetics of reversion to WT were compared by estimating
the time taken for 50% WT virus to be reached, using linear
interpolation of the log-transformed EM and WT viral loads. In
the animals infected with 4% WT virus, it took 63–75 days before
WT virus reached 50% of the total virus levels. In the case of the
animals infected with the 0.34% WT stock, WT virus levels never
exceeded EM virus levels to 75 days of follow up. Thus, lower
initial WT level was associated with an increased delay in WT
virus outgrowth.
Infection with escape mutant SIVmac239
Our analyses of biologic isolates of X4-tropic SHIVmn229 (for
KP9) and R5-tropic SHIVSF162P3 (for the AF9 epitope) strongly
suggested that the levels of WT virus in the inoculum have a major
bearing on the time needed for outgrowth of the WT virus.
However, it is difficult to completely exclude that these uncloned
viral stocks contain quasi-species with mutations at other sites or
compensatory mutations (although no clear pattern of such
mutations were seen during intensive cloning and sequencing).
To avoid these potential confounders we constructed a molecular
clone of the K165R KP9 EM virus within SIVmac239. This enabled
us to evaluate rates of reversion using a separate R5-tropic virus in
a very tightly controlled manner. We chose to infect naı ¨ve Mane-
A*10 negative pigtail macaques using plasmid DNA, an approach
we and others have previously used successfully, both with
attenuated and WT viruses [32,35–37]. Using clonal proviral
DNA to initiate the infection eliminates any possibility of
generating alternate viral quasispecies in vitro prior to in vivo
inoculation.
To first determine if infection with a mix of WT and EM
SIVmac239 conforms to the same general principles observed with
SHIVmn229 and SHIVSF162P3 we inoculated 2 naı ¨ve Mane-A*10
negative pigtail macaques using a 90:10 mix of EM:WT plasmid
DNA. Using our qRT-PCR assay to detect WT or EM virus, both
WT and EM virus grew readily for the first 2 weeks but WT virus
subsequently rapidly outgrew the EM virus (Figure 1E). The EM
virus slowly decayed later in infection. This pattern of outgrowth
of WT virus using a 90:10 EM:WT mix of SIV was almost
identical to that observed with the original 89:11 EM:WT
SHIVmn229 stock (Table 1).
We next evaluated the generation and outgrowth of revertant
WT virus following inoculation with pure clonal K165R EM
SIVmac239 (Figure 1F). Again we inoculated proviral DNA and an
infection was readily initiated in all 3 Mane-A*10 negative animals
studied. We observed an 8–10 day delay in the appearance of the
WT virus which took $63 days to exceed levels of the EM virus.
The patterns of growth of WT virus and decay of EM virus
following infection with 0% WT SIVmac239 were strikingly similar
to those observed with the passaged SHIVmn229 inocula with #4%
WT virus. A comparison of levels of WT and EM viruses across
the 6 strains used is shown in Figure 1G, with the viruses grouped
according to whether they have $ or ,10% WT in the inoculum.
Table 1. Reversion of KP9 and AF9 mutant viruses.
Epitope Virus
%WT in
Inocula
Ratio WT:EM in
Inocula
Recipient Animal
Number
Days to First
Detect WT
Days until
WT.EM
Reversion Rate at
50% WT
AF9 Passaged SHIVSF162P3 50% 1:1 6175 #6* 6 0.46
5904 #6 6 0.22
KP9 SHIVmn229 11% 1:9 4194 #7 7 0.42
4301 #7 14 0.18
H20 #7 7 0.35
1.7105 #71 4
KP9 SIVmac239 10% 1:10 3B14 #6 16 0.20
9532 #6 19 0.31
KP9 SHIVmn229 passage A 4% 1:25 6274 11 63 0.32
6366 11 75 0.35
KP9 SHIVmn229 passage B 0.34% 1:293 6238 8 .75
{ 0.083**
6255 8 .75 0.19**
KP9 SIVmac239 0% NA 5504 10 63 0.11
6176 10 63 0.067
6273 14 .77 0.064**
*#indicates WT virus detected at first time point sampled.
{.indicates WT virus levels did not exceed EM virus levels by last time point sampled.
**Reversion rates at 50% for these animals were determined by extrapolation.
doi:10.1371/journal.ppat.1000378.t001
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PLoS Pathogens | www.plospathogens.org 5 April 2009 | Volume 5 | Issue 4 | e1000378The grey shading in Figure 1G highlights the consistent 8–10 day
delay in appearance of the WT virus in the low WT virus inocula
and rapid outgrowth of WT virus in the high WT virus inocula.
Modelling reversion of WT virus
The experimental analysis above demonstrates that the rate of
reversion from WT to EM virus is linked to levels of WT virus in
the infecting inoculum. This is not unexpected since, all other
factors being equal, a halving of the initial proportion of WT virus
would be expected to require one additional doubling time before
the WT virus reached 50% of the initial inoculum. However, as
illustrated in Figure 2A, the observed effects of reducing the
proportion of WT virus are much stronger than expected by this
factor alone. In order to understand how the initial WT
proportion affects the subsequent dynamics of infection, we
modelled the dynamics of WT and EM virus following infection.
From previous work we expect that target cell number (the
number of uninfected CD4+ T cells available for infection) is
important to viral growth and the rate of reversion [11]. Therefore
we expect that early in infection reversion will be extremely rapid,
Figure 2. Dependence of reversion dynamics on the percentage of WT in the inoculum. (A) The time needed to reach 50% WT in total viral
load depends on the fraction of WT in the inoculum, and starts to increase rapidly with the decrease in initial percentage below approximately 10%.
(B) Dependence of reversion rate at 50% WT on the fraction of WT in the inoculum. In (A) and (B): full circle symbols, experimental data; open circles,
obtained by extrapolation; line, results of the model for rW2rM=3 610
24 mL/cell/day. (C) The observed reversion rate is proportional to the average
target cell number (Equation 3). The dashed line represents target cells in time. The red and the green full lines show how % WT in total viral load
grows if it is initially 10% or 0.25%, respectively. If WT does not reach 50% before target cells are depleted, then it will take much longer to overtake
EM. (D) Experimentally observed CD4+ T cell levels and % WT in the SHIVmn229-infected animal H20 (with initial 11% WT at KP9) and (E) in animal 6255,
infected with the passaged SHIVmn229 with 0.34% WT at KP9 conform to the theoretical pattern in (C).
doi:10.1371/journal.ppat.1000378.g002
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stage because there are fewer target cells to infect. We analyzed
the time taken to reach 50% WT virus using a simple ‘fixed
reversion rate’ model (dashed line in Figure 2A). This model
illustrates the increase in time to reach 50% WT that we would
expect solely from the decrease of WT fraction using a difference
in replicative capacities of WT and EM of 3.5610
24 mL/cell/day
[5,10,31]. We also analyzed a model that takes into account the
effects of decreasing viral growth with reduced target cell number
(solid line in Figure 2A) using Equation 2, for the same difference
in replicative capacities of WT and EM. For an initial WT content
between 50 and 10%, the time required for WT to reach 50% of
total viral load grows relatively slowly and almost linearly, as
expected just from the decrease in WT fraction. However, as the
proportion of WT decreases further, this time suddenly increases
much more rapidly than expected.
One prediction of this model is that not only will it take longer
to reach 50% WT when target cell dynamics are taken into
account, but that the reversion rate itself at 50% WT will be slower
with lower WT fraction in the inoculum. Indeed, the reversion
rate observed at 50% WT is significantly correlated to the fraction
of WT in the inoculum (Figure 2B, Table 1, Spearman correlation,
p=0.0005, r=0.788). The solid line shows the dependence of
reversion rate on initial WT fraction predicted by the model
Equation 2.
Analysis of the dynamics of WT and EM virus over time explains
this effect (Figure 2C). When high initial WT proportion is present,
the WT virus outgrows the EM virus in the early phase of infection,
when the pool of target cells for the virus is still nearly complete and
both virusesare still inan exponential growth phase (solidred line in
Figure 2C). Reducing WT virus levels slightly have little effect (just
delaying the time to 50% slightly, because of the additional time
required for the WT virus to grow). However, once the WT
proportion gets below a certain level, it will not reach the 50% level
before the peak of infection, and before the extensive depletion of
CD4+ T cells (solid green line in Figure 2C). The depletion of target
cells slows the growth of both viruses, but importantly also slows the
rate at which WT virus overtakes EM virus. If WT virus has not
already reached 50% by the time of peak viral load, its rate of
progress towards the 50% level is slowed dramatically, and it takes
much longer to outgrow EM. The same pattern is observed
experimentally, as shown by the examples of animals with initial
11.2% WT (Figure 2D) or with 0.34% WT (Figure 2E).
Biological implications of slow reversion to WT
Slow reversion to WT virus implies that the infecting virus
population is dominated by the less fit EM virus for longer periods
of time in comparison to animals with fast reversion. In theory, this
could result in lower viral loads and less pathogenic infections.
Goepfert and colleagues recently showed HIV-1 strains transmit-
ted with multiple Gag CD8 T cell escape mutations resulted in
overall lower viral loads [7]. However, the direct comparison to
otherwise similar virus strains is difficult in humans. Since we had
a large series of unvaccinated animals infected with the original
SHIVmn229 (which reverts rapidly) from previous infection studies
[28–30] and now multiple animals infected with a further passage
of SHIVmn229 with less WT virus at KP9 (that reverts slowly), we
compared the virologic outcome of infection with both viruses.
Both viruses grew effectively and exponentially during acute
infection (Figure 3A). However, animals infected with the passaged
viruses had much lower content of WT at peak and set point viral
loads (average 90% WT at peak in SHIVmn229 stock, versus only
5% WT at peak in passaged SHIVmn229, and 100% vs. 48% on
average respectively at the set point). The increased proportion of
WT virus at peak viral load in animals infected with SHIVmn229
stock is associated with an increased peak viral load in the animals
(Figure 3B): median peak viral load for SHIVmn229 stock-infected
animals was 1.24610
8 (95%CI from 9.6610
7 to 2.6610
8), and for
passaged SHIVmn229 it was 2.08610
6 (95%CI from 1.9610
6 to
8.0610
6, Mann-Whitney p=0.009). Set point viral load was also
significantly higher in animals infected with stock virus (Figure 3C):
for SHIVmn229 stock it was 9.4610
5 (95%CI from 7.3610
5 to
2.6610
6), and for the passaged virus it was 2.3610
4 (95%CI from
2.0610
3 to 3.8610
4, with Mann-Whitney p=0.0072). Thus, the
slow reversion of WT virus in animals infected with a low
proportion of WT virus has direct implications for the virological
outcome of infection.
Discussion
We conducted a large series of infections with combinations of
WT and CD8 T cell EM SHIV and SIV viruses. Using a sensitive
real-time PCR assay to simultaneously quantify levels of EM and
WT viremia, we found levels of WT virus in transmitted EM
viruses had a marked influence on the timing and rate of reversion
to WT. Where substantial amount of WT virus are present in the
inoculum, ‘‘reversion’’ (outgrowth of WT virus) is rapid, but if WT
virus is minimal or absent in the inoculum, there is a delay in
reversion and when reversion begins, it takes much longer to reach
the same levels as the EM virus. The consistency of these findings
across multiple SHIV and SIV isolates suggest this is a general
phenomenon of CD8 T cell EM reversion. This has important
consequences for HIV pathogenesis, since we found a delayed and
slow pattern of reversion of biologic SHIV quasispecies (where the
less fit EM virus dominates the infection for longer periods) is
associated with significantly reduced viral loads through to chronic
infection. Since virtually every HIV infection involves the selection
of EM viruses, transmission of EM viruses or mixes of EM and
WT virus will be the norm. Our studies suggest that in the subset
of around one quarter of new HIV infections, where 2 or more
viruses are transmitted [25], infections will be more pathogenic if
WT virus is present at significant levels in the transmitted
inoculum. This data provides rigorous experimental support to
recent large observational studies in humans, where HIV-1 Gag
CD8 T cell escape mutations in the donor were associated with
reduced viral loads in recipients [7,8].
A potential limitation to our findings of reduced viral load
following infection with EM SHIV quasispecies with very low
levels of WT virus is that we cannot exclude that mutations other
that the KP9 K165R EM present, including distant compensatory
mutations, in the passaged virus inocula could also be contributing
to the reduced VL upon transmission. Indeed, human HIV-1
transmission studies by Goepfert and colleagues suggest that
multiple Gag CD8 T cell epitope mutations may result in reduced
VLs in the recipients [7]. Since multiple HIV-specific CD8 T cell
responses restricted by different HLA class I alleles are typically
generated by infected subjects, transmission of viruses with
multiple CD8 T cell escape mutations should be the rule, rather
than the exception. Our experience with SHIVmn229-infected
pigtail macaques suggests that the KP9-specific CD8 T cell
response is highly immunodominant and the rapidly pathogenic
nature of the virus rarely permits generation of detectable
responses to other epitopes, suggesting the much lower proportions
of WT virus in the passaged SHIVmn229 viruses were primarily
responsible for the lower viral loads. None-the-less, larger studies
of cloned SIV viruses would assist in further defining the role of
individual mutations or combinations of CD8 T cell escape
mutations in reducing viral pathogenicity.
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so slow when it does not proceed during very early acute infection,
since the intrinsic fitness cost of the mutation should be the same
regardless of the timing of infection. Modelling reveals that
reversion rate is proportional to target cell number [11]. This
explains why, in majority of cases, we observe the maximum
reversion rate early in infection. If WT is initially present in a
sufficient amount, so that it reaches 50% of total viral load during
the early phase of exponential growth, before target cells are
substantially depleted, reversion is rapid. The time needed to
overtake EM will increase slowly with decrease in percent of WT
in the inoculum. However, for initial WT fractions below a certain
threshold, WT will not overtake EM before the peak viral load. In
this case, the extensive depletion of target cells will slow down the
reversion rate and markedly increase the time to 50% WT.
A caveat to these studies is the study of CXCR4-utilizing SHIV
viruses for these analyses. Since these viruses deplete all naı ¨ve
CXCR4-expressing CD4 T cells, the depletion of peripheral CD4
T cells should approximate total CD4 T cell loss, and thus
frequent monitoring of peripheral CD4 T cells allows us to model
CD4 T cell depletion and reversion. Typical CCR5-utilizing HIV-
1 and SIV strains target memory CD4 T cells which are most
abundant in the gastrointestinal tract and rapidly depleted during
acute infection. These cells are less amenable to the frequent
monitoring required to correlate of the levels of CD4 T cell
depletion with the rate of reversion of viral escape mutants.
However, previous analysis comparing the dynamics of CD4+ T
cell depletion in the blood during SHIV infection and in the gut
following SIV infection suggest that the dynamics are remarkably
similar [38,39]. Further analyses of infection of macaques with
CCR5-utilizing SIV strains containing CD8 T cell escape
mutations and frequent gut biopsies to assess memory CD4 T
cell depletion are warranted. Additionally, although CD4 T cells
are typically responsible for the majority of virus replication [40],
the use of CCR5-tropic viruses would permit a better assessment
of the contribution of non-CD4 T cell targets such as macrophages
to virus growth and reversion of escape mutant viruses.
Although we studied a modest number of animals within each
group, our findings were consistent across both SHIV and SIV
infection models using both biological isolates (for the SHIV
studies) and molecular clones (for the SIV studies). When WT
virus comprised $10% of the inoculum, expansion of WT virus
during acute infection was exponential and uniform across
SHIVmn229, SHIVSF162P3 and SIVmac239 infection models. When
WT virus was ,4% of the inoculum, there was a consistent delay
of 8–11 days until WT virus is first detected even at very low levels.
This occurs during the critical window of early virus dissemina-
tion, the so-called ‘‘eclipse’’ phase of very early acute HIV-1
infection of humans [25,41]. Our studies support previous HIV-1
transmission analyses that suggest that when EM variants are
primarily transmitted (likely the majority of cases) a less fit EM
virus will predominate during acute infection that may be less
pathogenic [7,8]. Our studies suggest ‘‘founder’’ effects of
transmission of EM viruses into new hosts could have a bearing
on overall disease pathogenesis of HIV-1 and potentially other
variable RNA viruses such as Hepatitis C Virus. We speculate that
Figure 3. Reduced pathogenicity of passaged SHIVmn229. (A) Comparison of mean (6SEM) viral load of 21 animals infected with the same
original SHIVmn229 stock (89% EM, 11% WT) to four animals inoculated with passaged SHIVmn229 isolates containing less WT virus (4% or 0.3%). (B)
Comparison of individual peak viral loads. (C) Comparison of individual set point viral loads.
doi:10.1371/journal.ppat.1000378.g003
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by even partially successful prevention strategies such as
vaccination, the infection may result in lower viral loads, delayed
disease and reduced forward transmission.
Author Contributions
Conceived and designed the experiments: LL JP MPD SJK. Performed the
experiments: LL JCR CSF SA RC JH MB JP. Analyzed the data: LL JP
MPD SJK. Contributed reagents/materials/analysis tools: RC DFJP.
Wrote the paper: LL JP MPD SJK.
References
1. Altfeld M, Allen TM (2006) Hitting HIV where it hurts: an alternative approach
to HIV vaccine design. Trends Immunol 27: 504–510.
2. Goulder PJ, Watkins DI (2008) Impact of MHC class I diversity on immune
control of immunodeficiency virus replication. Nat Rev Immunol 8: 619–630.
3. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, et al. (2004)
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med
10: 275–281.
4. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV
evolution: CTL escape mutation and reversion after transmission. Nat Med 10:
282–289.
5. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, et al. (2005) Rapid viral
escape at an immunodominant simian-human immunodeficiency virus cytotoxic
T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 79: 5721–5731.
6. Allen TM, Altfeld M, Yu XG, O’Sullivan KM, Lichterfeld M, et al. (2004)
Selection, transmission, and reversion of an antigen-processing cytotoxic T-
lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
J Virol 78: 7069–7078.
7. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, et al. (2008)
Transmission of HIV-1 Gag immune escape mutations is associated with
reduced viral load in linked recipients. J Exp Med 205: 1009–1017.
8. Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, et al. (2008)
Transmission of HIV-1 CTL escape variants provides HLA-mismatched
recipients with a survival advantage. PLoS Pathog 4: e1000033. doi:10.1371/
journal.ppat.1000033.
9. Fernandez CS, Smith MZ, Batten CJ, De Rose R, Reece JC, et al. (2007)
Vaccine-induced T cells control reversion of AIDS virus immune escape
mutants. J Virol 81: 4137–4144.
10. Loh L, Petravic J, Batten CJ, Davenport MP, Kent SJ (2008) Vaccination and
timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog 4:
e12. doi:10.1371/journal.ppat.0040012.
11. Petravic J, Loh L, Kent SJ, Davenport MP (2008) CD4+ target cell availability
determines the dynamics of immune escape and reversion in vivo. J Virol 82:
4091–4101.
12. Loh L, Kent SJ (2008) Quantification of simian immunodeficiency virus
cytotoxic T lymphocyte escape mutant viruses. AIDS Res Hum Retroviruses 24:
1067–1072.
13. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, et al. (2007)
Compensatory mutation partially restores fitness and delays reversion of escape
mutation within the immunodominant HLA-B*5703-restricted Gag epitope in
chronic human immunodeficiency virus type 1 infection. J Virol 81: 8346–8351.
14. Asquith B, McLean AR (2007) In vivo CD8+ T cell control of immunodeficiency
virus infection in humans and macaques. Proc Natl Acad Sci U S A 104:
6365–6370.
15. Long EM, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, et al. (2000)
Gender differences in HIV-1 diversity at time of infection. Nat Med 6: 71–75.
16. Zhu T, Mo H, Wang N, Nam DS, Cao Y, et al. (1993) Genotypic and
phenotypic characterization of HIV-1 patients with primary infection. Science
261: 1179–1181.
17. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, et al. (2003)
Infection with multiple human immunodeficiency virus type 1 variants is
associated with faster disease progression. J Virol 77: 12921–12926.
18. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, et al. (1992) Selective
transmission of human immunodeficiency virus type-1 variants from mothers to
infants. Science 255: 1134–1137.
19. Wolfs TF, Zwart G, Bakker M, Goudsmit J (1992) HIV-1 genomic RNA
diversification following sexual and parenteral virus transmission. Virology 189:
103–110.
20. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, et al. (2002) Virus population
homogenization following acute human immunodeficiency virus type 1
infection. J Virol 76: 11953–11959.
21. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, et al. (2004)
Incidence of HIV-1 dual infection and its association with increased viral load set
point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis
190: 1355–1359.
22. Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, et al. (2004) Multiple
V1/V2 env variants are frequently present during primary infection with human
immunodeficiency virus type 1. J Virol 78: 11208–11218.
23. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004)
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual trans-
mission. Science 303: 2019–2022.
24. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008)
Deciphering human immunodeficiency virus type 1 transmission and early
envelope diversification by single-genome amplification and sequencing. J Virol
82: 3952–3970.
25. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008)
Identification and characterization of transmitted and early founder virus
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105:
7552–7557.
26. Smith MZ, Dale CJ, De Rose R, Stratov I, Fernandez CS, et al. (2005) Analysis
of Pigtail Macaque Major Histocompatibility Complex Class I Molecules
Presenting Immunodominant Simian Immunodeficiency Virus Epitopes. J Virol
79: 684–695.
27. Pratt BF, O’Connor DH, Lafont BA, Mankowski JL, Fernandez CS, et al. (2006)
MHC class I allele frequencies in pigtail macaques of diverse origin.
Immunogenetics 58: 995–1001.
28. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, et al. (2007)
Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus
Priming and Boosting Vaccines in Pigtail Macaques. J Virol 81: 292–300.
29. Dale CJ, De Rose R, Stratov I, Chea S, Montefiori D, et al. (2004) Efficacy of
DNA and Fowlpoxvirus prime/boost vaccines for Simian/Human Immunode-
ficiency Virus. J Virol 78: 13819–13828.
30. Dale CJ, Liu XS, De Rose R, Purcell DF, Anderson J, et al. (2002) Chimeric
human papilloma virus-simian/human immunodeficiency virus virus-like-
particle vaccines: immunogenicity and protective efficacy in macaques. Virology
301: 176–187.
31. Loh L, Batten CJ, Petravic J, Davenport MP, Kent SJ (2007) In vivo fitness costs
of different Gag CD8 T cell escape mutant simian-human immunodeficiency
viruses in macaques. J Virol 81: 5418–5422.
32. Kent SJ, Dale CJ, Preiss S, Mills J, Campagna D, et al. (2001) Vaccination with
attenuated simian immunodeficiency virus by DNA inoculation. J Virol 75:
11930–11934.
33. Gibbs JS, Regier DA, Desrosiers RC (1994) Construction and in vitro properties
of SIVmac mutants with deletions in nonessential genes. AIDS Res Hum
Retroviruses 10: 333–342.
34. Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, et al. (2006) Rapid
Reversion of Sequence Polymorphisms Dominates Early HIV-1 Evolution.
J Virol 81: 193–201.
35. Liska V, Khimani AH, Hofmann-Lehmann R, Fink AN, Vlasak J, et al. (1999)
Viremia and AIDS in rhesus macaques after intramuscular inoculation of
plasmid DNA encoding full-length SIVmac239. AIDS Res Hum Retroviruses
15: 445–450.
36. Kent SJ, Dale CJ, Preiss S, Purcell DF (2002) Evidence of recombination
between 39 and 59 LTRs in macaques inoculated with SIV DNA. AIDS Res
Hum Retroviruses 18: 227–230.
37. Kent SJ, Cameron PU, Reece JC, Thomson P, Purcell DF (2001) Attenuated
and wild type HIV-1 infections and long terminal repeat mediated gene
expression from plasmids delivered by gene gun to human skin ex vivo and
macaques in vivo. Virology 287: 71–78.
38. Davenport MP, Zhang L, Shiver JW, Casmiro DR, Ribeiro RM, et al. (2006)
Influence of peak viral load on the extent of CD4+ T-cell depletion in simian
HIV infection. J Acquir Immune Defic Syndr 41: 259–265.
39. Wilson DP, Mattapallil JJ, Lay MD, Zhang L, Roederer M, et al. (2007)
Estimating the infectivity of CCR5-tropic simian immunodeficiency virus
SIV(mac251) in the gut. J Virol 81: 8025–8029.
40. van der Ende ME, Schutten M, Raschdorff B, Grossschupff G, Racz P, et al.
(1999) CD4 T cells remain the major source of HIV-1 during end stage disease.
AIDS 13: 1015–1019.
41. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003)
Dynamics of HIV viremia and antibody seroconversion in plasma donors:
implications for diagnosis and staging of primary HIV infection. Aids 17:
1871–1879.
Reversion to Wild Type Correlates with Viral Load
PLoS Pathogens | www.plospathogens.org 9 April 2009 | Volume 5 | Issue 4 | e1000378